|
|
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
|
|
|
|
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
|
|
|
|
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
|
|
|
|
Emergent BioSolutions to Participate in Upcoming Investor Conferences
|
|
|
|
Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
|
|
|
|
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
|
|
|
|
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
|
|
|
|
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
|
|
|
|
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
|
|
|
|
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
|
|
|
|
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
|
|
|
|
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
|
|
|
|
Emergent BioSolutions Announces Addition to Russell 3000® Index
|
|
|
|
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
|
|
|
|
NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF DERIVATIVE ACTIONS
|
|
|
|
Summary Notice of Pendency and Proposed Settlement of Derivative Actions
|
|
|
|
Emergent BioSolutions to Participate in Upcoming Investor Conferences
|
|
|
|
Emergent BioSolutions Reports First Quarter 2025 Financial Results
|
|
|
|
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
|
|
|
|
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
|
|
|
|
Emergent BioSolutions Announces Stock Repurchase Program
|
|
|
|
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
|
|
|
|
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
|
|
|
|
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
|
|
|
|
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
|
|
|
|
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
|
|
|
|
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
|
|
|
|
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
|
|
|
|
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
|
|
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
|
|
|
|
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
|
|
|
|
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
|
|
|
|
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
|
|
|
|
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
|
|
|
|
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
|
|
|
|
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
|
|
